Infiltrating macrophages in extratumoural tissues after brachytherapy of uveal melanoma

Acta Ophthalmologica

Volumn 90, Issue 4, 2012, Pages 341-349

  Toivonen, Päivi ^a   Kivelä, Tero ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

case control study; macrophages; melanoma; microcirculation; radiation damage

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PG M1; UNCLASSIFIED DRUG;

ARTICLE; BRACHYTHERAPY; CASE CONTROL STUDY; CHOROID; CHOROID MELANOMA; CILIARY BODY MELANOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA LIMBUS; ENUCLEATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LEUKOCYTE COUNT; MACROPHAGE MIGRATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION RESPONSE; SCLERA; TISSUE DISTRIBUTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR NECROSIS; UVEA MELANOMA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BRACHYTHERAPY; CASE-CONTROL STUDIES; CELL COUNT; CELL MOVEMENT; CHOROID; CILIARY BODY; EYE ENUCLEATION; HUMANS; IMMUNOENZYME TECHNIQUES; MACROPHAGES; MELANOMA; MICROCIRCULATION; SCLERA; UVEAL NEOPLASMS;

EID: 84861618640     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.01985.x     Document Type: Article

References (36)

1. Aalto Y, Eriksson L, Seregard S, Larsson O, &, Knuutila S, (2001): Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 42: 313-317.
2. Camelo S, Kezic J, Shanley A, Rigby P, &, McMenamin PG, (2006): Antigen from the anterior chamber of the eye travels in a soluble form to secondary lymphoid organs via lymphatic and vascular routes. Invest Ophthalmol Vis Sci 47: 1039-1046.
3. Clarijs R, Schalkwijk L, Ruiter DJ, &, de Waal RM, (2003): EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44: 1801-1806.
4. Diener-West M, Earle JD, Fine SL, et al., (2001): The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 119: 969-982.
5. Djano J, Griffin B, van Bruggen I, &, McMenamin PG, (1999): Environmental scanning electron microscopic study of macrophages associated with the tunica vasculosa lentis in the developing rat eye. Br J Ophthalmol 83: 1384-1385.
6. Fuchs A, Kivelä T, Tarkkanen A, &, Laatikainen L, (1988): Histopathology of enucleated intraocular melanomas irradiated with cobalt and ruthenium plaques. Acta Ophthalmol (Copenh) 66: 255-266.
7. Fuchs U, Kivelä T, Summanen P, Immonen I, &, Tarkkanen A, (1992): An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am J Pathol 141: 169-181.
8. Gunduz K, Shields CL, Shields JA, Cater J, &, Brady L, (2000): Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension. Am J Ophthalmol 130: 97-102.
9. Heikkonen J, Summanen P, Immonen I, Tommila P, Toivola H, Forss M, &, Tarkkanen A, (1992): Radiotherapy of malignant melanoma of the uvea with I-125 seeds. Acta Ophthalmol (Copenh) 70: 780-785.
10. Hogan MJ, Alvarado JA, &, Weddell JE, (1971): Histology of the human eye. An atlas and textbook. Philadelphia, PA: W.B. Saunders.
11. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, &, Littman DR, (2000): Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20: 4106-4114.
12. Kivelä T, (1995): Immunohistochemical staining followed by bleaching of melanin: a practical method for ophthalmic pathology. Br J Biomed Sci 52: 325-326.
13. Liszauer AD, Brownstein S, Corriveau C, &, Deschenes J, (1990): A clinicopathological study of seven globes enucleated after primary radiation therapy for malignant melanoma of the choroid or ciliary body. Can J Ophthalmol 25: 340-344.
14. Lommatzsch PK, Werschnik C, &, Schuster E, (2000): Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 238: 129-137.
15. Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos NE, &, Jager MJ, (2008): Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci 49: 505-510.
16. Mäkitie T, Tarkkanen A, &, Kivelä T, (1998): Comparative immunohistochemical oestrogen receptor analysis in primary and metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol 236: 415-419.
17. Mäkitie T, Summanen P, Tarkkanen A, &, Kivelä T, (1999a): Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci 40: 2471-2480.
18. Mäkitie T, Summanen P, Tarkkanen A, &, Kivelä T, (1999b): Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 91: 359-367.
19. + cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 42: 1414-1421.
20. McMenamin PG, Djano J, Wealthall R, &, Griffin BJ, (2002): Characterization of the macrophages associated with the tunica vasculosa lentis of the rat eye. Invest Ophthalmol Vis Sci 43: 2076-2082.
21. Messmer E, Bornfeld N, Foerster M, Schilling H, &, Wessing A, (1992): Histopathologic findings in eyes treated with a ruthenium plaque for uveal melanoma. Graefes Arch Clin Exp Ophthalmol 230: 391-396.
22. Polak ME, Borthwick NJ, Johnson P, Hungerford JL, Higgins B, Di PS, Jager MJ, &, Cree IA, (2007): Presence and phenotype of dendritic cells in uveal melanoma. Br J Ophthalmol 91: 971-976.
23. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, &, Becher R, (1996): Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347: 1222-1225.
24. Schilling H, Sehu KW, &, Lee WR, (1997): A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Invest Ophthalmol Vis Sci 38: 2081-2092.
25. Schlesselman JJ, (1982): Case-control studies: design, conduct, analysis. New York: Oxford University Press.
26. Schmollinger JC, &, Dranoff G, (2004): Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy. Apoptosis 9: 309-313.
27. Schroedl F, Brehmer A, Neuhuber WL, Kruse FE, May CA, &, Cursiefen C, (2008): The normal human choroid is endowed with a significant number of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1)-positive macrophages. Invest Ophthalmol Vis Sci 49: 5222-5229.
28. Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, &, Brady LW, (2000): Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 118: 1219-1228.
29. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM, &, Rees RC, (1997): Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 19: 22-28.
30. Streilein JW, Wilbanks GA, Taylor A, &, Cousins S, (1992): Eye-derived cytokines and the immunosuppressive intraocular microenvironment-A review. Curr Eye Res 11: 41-47.
31. The Collaborative Ocular Melanoma Study Group (1998): Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol 125: 745-766.
32. Toivonen P, &, Kivelä T, (2006): Pigmented episcleral deposits after brachytherapy of uveal melanoma. Ophthalmology 113: 865-873.
33. Toivonen P, Mäkitie T, Kujala E, &, Kivelä T, (2003): Macrophages and microcirculation in regressed and partially regressed irradiated choroidal and ciliary body melanomas. Curr Eye Res 27: 237-245.
34. de Waard-Siebinga I, Hilders CG, Hansen BE, van Delft JL, &, Jager MJ, (1996): HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol 234: 34-42.
35. White VA, Chambers JD, Courtright PD, Chang WY, &, Horsman DE, (1998): Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 83: 354-359.
36. Wilbanks GA, &, Streilein JW, (1991): Studies on the induction of anterior chamber-associated immune deviation (ACAID).1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral-blood. J Immunol 146: 2610-2617.